Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jonathan Julia

Interventional Pain Medicine Kyle, TX Medical Doctor

NPI 1134577174 CMS profile 8800269

4210 Benner, Kyle, TX 78640

Open in the dashboard

General payments

$17,047

432 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Julia of Kyle, TX is reported in the CMS Open Payments database as having received $17,047 across 432 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,819 79
2024 General $3,782 86
2023 General $2,621 66
2022 General $5,391 147
2021 General $1,988 44
2020 General $447 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Julia
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jonathan Julia were reported at $2,819. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jonathan Julia Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $447 $382 $122–$1,109 $114
2021 $1,988 $552 $167–$1,554 $132
2022 $5,391 $605 $187–$1,924 $149
2023 $2,621 $671 $195–$1,915 $160
2024 $3,782 $684 $206–$1,837 $164
2025 $2,819 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Abbott Laboratories $11,202 271 payments
  2. Medtronic, Inc. $2,102 62 payments
  3. Spinal Simplicity, LLC $1,657 60 payments
  4. Boston Scientific Corporation $481 12 payments
  5. SI-BONE, Inc. $372 3 payments
  6. Vertos Medical, Inc. $354 4 payments
  7. Medtronic USA, Inc. $297 7 payments
  8. Nevro Corp. $191 4 payments
  9. Relievant Medsystems, Inc. $138 4 payments
  10. Mallinckrodt Hospital Products Inc. $122 1 payment
  11. Other $132 4 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $16,334 422 payments
  2. Travel and Lodging $699 9 payments
  3. Education $14 1 payment
Products named General payments · program years 2020–2025
  1. OCTRODE $3,021 92 payments
  2. PROCLAIM Neuromodulation $2,941 72 payments
  3. HA MINUTEMAN G3-R $1,657 60 payments
  4. PROCLAIM Neuromodulation $1,421 21 payments
  5. INTELLIS ADAPTIVESTIM $928 24 payments
  6. Proclaim IPG $893 22 payments
  7. PROCLAIM Neuromodulation $630 21 payments
  8. VANTA ADAPTIVESTIM $561 12 payments
  9. PROCLAIM Neuromodulation $542 9 payments
  10. PROCLAIM Neuromodulation $505 11 payments
  11. Other $4,083 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

3,155

Median for Interventional Pain Management: 1,220

Drug cost

$63,374

Median for Interventional Pain Management: $39,344

Branded share of claims

48.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,049 $22,510
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 326 $7,597
Pregabalin Generic 328 $6,772
Xtampza Er Oxycodone Myristate Brand 12 $4,139
Oxycontin Oxycodone Hcl Brand 14 $4,018
Gabapentin Generic 292 $3,227
Lidocaine Generic 27 $2,248
Morphine Sulfate Er Morphine Sulfate Brand 115 $2,230
Tramadol Hcl Generic 260 $1,796
Tizanidine Hcl Generic 172 $1,760

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$289,663

Of which drugs: $6,601

Medicare patients

503

Average age 73

Services billed

4,991

311 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Depression 36%
Diabetes 34%
Chronic kidney disease 25%
Osteoporosis 20%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 47 720 $65

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

432 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record